Redeye repeats its view on Sedana Medical’s 2024 sales growth target to be conservative, as is demonstrated by the Q1 sales. With a relatively nearing FDA filing (Q1 2025), the US part of the equity story will become more important going forward. In the meantime, we will keep an extra eye on sales in Spain and the UK. We leave our fair value range unchanged.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Sedana Medical Q1 - Set to beat conservative sales target

© Modular Finance, source Nordic Press Releases